ATG4B and temporal arteritis: These results collectively indicated that pharmacological inhibition of ATG4B with the novel inhibitor Am-F4a or TIC might effectively inhibit the viability of GCa cells via suppressing ATG4B activity and improve anti-GCa efficacy of 5-FU.